Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods.
OBJECTIVE
To develop an in silico model that provides an accurate prediction of the relative solubility of the lipophilic anticancer agent docetaxel in various excipients.


METHODS
The in silico solubility of docetaxel in the excipients was estimated by means of the solubility (delta) and Flory-Huggins interaction (chi (FH)) parameters. The delta values of docetaxel and excipients were calculated using semi-empirical methods and molecular dynamics (MD) simulations. Cerius(2) software and COMPASS force-field were employed for the MD simulations. The chi (FH) values for the binary mixtures of docetaxel and excipient were also estimated by MD simulations.


RESULTS
The values obtained from the MD simulations for the solubility of docetaxel in the various excipients were in good agreement with the experimentally determined values. The simulated values for solubility of docetaxel in tributyrin, tricaproin and vitamin E were within 2 to 6% of the experimental values. MD simulations predicted docetaxel to be insoluble in beta-caryophyllene and this result correlated well with experimental studies.


CONCLUSIONS
The MD model proved to be a reliable tool for selecting suitable excipients for the solubilization of docetaxel.
Huynh
Loan
L
Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Grant
Justin
J
Leroux
Jean-Christophe
JC
Delmas
Pascal
P
Allen
Christine
C
D000465:Algorithms; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D003198:Computer Simulation; D000077143:Docetaxel; D005079:Excipients / Q000737:chemistry*; D006860:Hydrogen Bonding; D008055:Lipids / Q000737:chemistry; D008958:Models, Molecular; D012995:Solubility; D043823:Taxoids / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology
D000972:Antineoplastic Agents, Phytogenic; D005079:Excipients; D008055:Lipids; D043823:Taxoids; D000077143:Docetaxel
Adv Drug Deliv Rev. 2002 Nov 1;54 Suppl 1:S77-98
12460717
Int J Cancer. 2001 Mar 15;91(6):840-5
11275989
Pharm Res. 2006 Apr;23(4):752-8
16550475
Chem Pharm Bull (Tokyo). 2005 Aug;53(8):893-8
16079515
J Pharm Sci. 1999 Nov;88(11):1182-90
10564068
J Chromatogr A. 2005 Jan 28;1064(1):85-95
15729823
Mol Cancer Ther. 2003 Mar;2(3):227-33
12657717
J Control Release. 2003 Sep 19;92(1-2):19-26
14499182
Pharm Res. 2004 Feb;21(2):201-30
15032302
J Colloid Interface Sci. 2004 Jun 1;274(1):55-68
15120278
J Pharm Sci. 1997 Dec;86(12):1458-63
9423162
J Control Release. 2002 Dec 13;85(1-3):51-9
12480311
J Control Release. 1999 Apr 19;58(3):271-8
10099152
Drug Discov Today. 2006 Nov;11(21-22):1012-8
17055411
Nat Mater. 2004 Sep;3(9):638-44
15300242
Int J Pharm. 2003 Jun 4;258(1-2):193-201
12753765
J Clin Oncol. 1995 Oct;13(10):2643-55
7595719
J Control Release. 2005 Feb 2;102(2):415-25
15653161
N Engl J Med. 1995 Apr 13;332(15):1004-14
7885406
J Chromatogr A. 2005 May 6;1073(1-2):347-53
15909540
J Control Release. 1998 Jan 2;50(1-3):135-43
9685880
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
11259830
Mol Pharmacol. 2006 Dec;70(6):1935-45
16998007
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6920-4
7624344
J Med Chem. 1995 Sep 15;38(19):3821-8
7562913